Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT05001945
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT05001945
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05001945. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2022-09-07 (actual). Results posted on 2024-01-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
- Acronym
- Target-HTN
- Condition
- Hypertension, Renal
- Intervention (Drug)
- MLS-101 (Part I)
- Intervention (Other)
- Placebo (Part I)
- Intervention (Other)
- Placebo (Part II)
- Intervention (Drug)
- MLS-101 (Part II)
- Lead sponsor
- Mineralys Therapeutics Inc.
Record details
- Record id
cardio:ct-nct05001945- Content hash
91e211e7fe6ab434994ae4b9d4177fe54434c310340c5ca4f9b8aa81db65da45